Introduction

1
Permanent conductive hearing loss can result from otosclerosis, a disease in which abnormal 2 bone growth may impede the movement of the stapes bone and impair cochlear function. 3
Examinations of temporal bones suggest that the disease presents bilaterally in approximately 4 70-80% of cases (Hueb et al., 1991; Menger & Tange, 2003) . Temporal bone studies have 5 estimated a prevalence for otosclerosis of between 2.5% (Declau et al, 2001 ) and 8.3% 6 (Altman et al, 1967) . These estimates represent the combined sum of both symptomatic 7 (clinical otosclerosis) and asymptomatic (histologic otosclerosis) cases. The proportion of 8 these cases that correspond to clinical otosclerosis, where the disease actually interferes with 9 hearing function, has been estimated to be between 12% (Altman et al, 1967) and 15% 10 (Guild, 1944) . These data therefore suggest that the prevalence of clinical otosclerosis in the 11 population lies between 0.3% and 1.2%. It is estimated that sensorineural hearing loss also 12 arises in about 10% of clinical otosclerosis cases (Browning & Gatehouse, 1992; Ramsay & 13 Linthicum, 1994) and accounts for approximately 5-6% of cases at large cochlear implant 14 centres (Tange R., personal communication, 2016), which if accurate would correspond to a 15 prevalence for mixed losses arising from otosclerosis of 0.1% or lower. 16 hearing aid. In cases where an acoustic hearing aid cannot provide sufficient amplification or 26 is not tolerated (e.g. ear infections) or surgical correction is not appropriate, a bone-anchored 27 hearing device (BAHD) may be used to deliver acoustical energy to the cochlea via bone 28 conduction (Tjellström & Håkansson, 1995) . In cases of moderate-to-severe loss where both 29 acoustic and bone-anchored hearing aids are unsuccessful or contraindicated, a middle-ear 30 implant may also be considered. 31
32
In the United Kingdom (UK), the treatment options for individuals with a severe-to-profound 33 mixed hearing loss are limited. The severity of the loss means that an acoustic hearing aid 34 alone is unlikely to provide benefit without surgical intervention to address the conductive 35 component. The rate of successful stapes surgery in this patient group has been estimated to 36 be approximately 60% (defined as the closure of the air-bone gap to <10 dB) and lower than 37 that observed in patients with mild or moderate losses (Kisilevsky et al, 2010) . The capacity 38 of a BAHD device to provide benefit in these patients is also limited by its ability to provide 39 sufficient energy transfer to the cochlea to overcome the sensorineural component of the loss. 40
The introduction of more powerful BAHDs has expanded the candidacy range but aiding 41 review of those assessed in previous clinical studies of DACI (Busch et al 2013; Lenarz et al 100 2013) and are listed in Table 1.  101   102 Finally, respondents were reminded of the characteristics of the patient group of interest 103 before being asked three questions about the clinical appropriateness of the DACI device, 104 whether respondents would be willing to refer these patients into a trial of the DACI device, 105 and at what stage in their treatment would they be willing to refer. For the latter, the options 106
given were: 'Even before initial stapes surgery', 'Only after stapes surgery', 'Only after 107 revision stapes surgery', 'Other (please specify)', and 'I don't know'. The DACI device was 108 not described by name but rather as a device which: (Fig. 2) . All but two (93%; 95% CI 78.7 to 98.2) indicated that 141 their preferred management would include amplification via conventional acoustic hearing 142 aids with 11 (37%; 95% 21.9 to 54.5) also indicating that they would recommend hearing 143 therapy in addition to amplification. Only two respondents suggested alternative treatment 144 options, which were the provision of a bone anchored hearing device and cochlear 145
implantation. 146 147
Respondents' choices for the most important outcome to assess when measuring treatment 148 benefit are shown in Table 1 . No outcome domain was chosen by a statistical majority of7 respondents either as the most or second most important outcome. The most frequently 150 chosen outcome across either response option was self-reported quality of life, with 55% of 151 respondents (95% CI 37.5 to 71.6) selecting it as either the most or second most important 152 outcome to assess treatment benefit. 153
154
When asked about whether DACI would be an appropriate treatment option for the patient 155 group of interest, 25 of the 29 respondents (86%; 95% 69.4 to 94.5) indicated that it was, 156 with the remainder selecting 'I do not know'. None indicated that it was inappropriate. All 157 those who considered it appropriate also indicated a willingness to refer their patients into a 158 future trial. However, there was variability in when respondents would be willing to refer 159 patients with 9 (38%; 95% 21.2 to 57.3) willing to do so even before stapes surgery had been 160 attempted and 8 (33%; 95% 18.0 to 53.3) willing only after stapes surgery had been carried 161 out. One respondent indicated that they might be willing to refer before stapes surgery but 162 only if further evidence for the effectiveness of the DACI was available. Three respondents 163 listed other criteria for referral, which were: (1) only after revision stapes surgery; (2) only 164 after discussion with the patient; and (3) only after full investigation of non-surgical aiding 165
options. 166 167
Nineteen clinical professionals participated in the consensus exercise. An analysis of the 168 transcript of the face-to-face facilitated discussion identified sixteen statements around which 169 consensus was considered possible. Table 2 lists these statements along with the levels of 170 agreement after one and two rounds of voting. The consensus was that stapes surgery, either 171 with or without a hearing aid, is the best available treatment for advanced otosclerosis and a 172 hearing aid trial is recommended prior to surgery, if that patient is willing. Bone-anchored 173 hearing devices are an option for some patients and a headband trial would alwaysrecommended, but the limit of candidacy for these devices is considered to be BC thresholds 175 at 50 dB HL. Bone-anchored hearing devices are considered to be not powerful enough for 176 patients whose BC thresholds are greater than 55 dB HL. 177
178
The consensus was that there is a lack of clear alternative treatment options for those who 179 have already received the best available treatment, who are outside criteria for both bone 180 conduction hearing devices and cochlear implantation, and who still receive insufficient 181 benefit from their hearing aids. These patients would therefore be referred for an implantable 182 intervention such as a DACI as long as the odds of the patient receiving additional benefit 183 over their hearing aids were favourable and similar to those expected for benefit from a 184 cochlear implant. The consensus was also that further trials are needed and that would be 185 supported by clinical professionals involved in the management of these patients. 186
187
Discussion
188
It is perhaps as informative to examine the statements that did not reach the required level of 189 agreement as it is to identify where consensus was reached. The survey responses suggest 190 that stapes surgery would still be offered to some patients with an air-bone gap as small as 20 191 dB. The willingness of respondents to carry out stapes surgery even when benefit could be 192 limited due to poor cochlear function could reflect the fact that pre-operative bone conduction 193 levels may under-estimate the actual benefit achievable from stapes surgery (Shea et al., 194 1999 ). However, the observed consensus on the need for favourable odds of improvement to 195 warrant referral for a DACI suggests that there will be a lower limit of cochlear function 196 beyond which clinicians will not be willing to refer patients. It is therefore important for 197 future studies to characterise the relationship between pre-operative speech perception and It would also seem logical to assume that there will be an upper limit for the speech 205 perception abilities of these patients beyond which DACI would either been seen as 206 unnecessary or inappropriate. However, consensus was not reached on a statement that 207 restricted referral to those with speech discrimination up to 50% correct, a threshold that has 208 previously been used to define insufficient benefit from acoustic hearing aids in patients with 209 more profound losses (NICE 2009). The failure to reach consensus on this point could reflect 210 a belief that the threshold for referral should be more or less restrictive, but it could also be 211 that respondents believed 'insufficient benefit from hearing aids' cannot be defined 212 adequately or reliably in terms of a fixed threshold on a test of speech perception conducted 213 in the artificial environment of an audiology testing booth. In the absence of an agreed 214 threshold, such a judgement could be based on patient self-report of benefit in real life 215 situations following the confirmed completion of a hearing aid trial. 216
217
The failure to reach a consensus on whether clinicians were willing to refer for a DACI where 218 a conductive component remained suggests that referral would be conditional on the outcome 219 of stapes surgery in those patients where surgery would be recommended. However, the 220 group failed to reach consensus on a general statement indicating that stapes surgery would 221 be required before referral for a DACI could be recommended. This result is compatible with 222 the fact that the needs of patients for whom stapes surgery is not recommended were 223 considered to be unmet by the available treatment options. Their apparent willingness to refer 224 some patients for a DACI even without having conducted stapes surgery could also have 225 reflected their views on the needs of patients with losses that are predominantly sensorineural 226 in origin. The current study did not ask about such patients as it fell outside the current 227 labelling of the device at the time the study was conducted (Cochlear, 2013) . 228
229
The current study aimed to inform the design of a future trial of DACI in the UK, including 230 identifying the target patient population for whom the intervention is appropriate and needed. 231 Table 3 lists proposed inclusion and exclusion criteria for a trial based on an analysis of the 232 statements upon which the respondents reached consensus. The results of the current practice 233 survey and the consensus exercise both suggest that the trial design needs to account for two 234 groups: (1) those for whom stapes surgery is recommended where referral for a DACI would 235 only be supported after that surgery has been conducted; (2) those for whom stapes surgery 236
would not be clinically appropriate and for whom referral would be supported without prior 237 surgical intervention. In both cases, the comparator to the DACI should be a trial of an 238 acoustic hearing aid in combination with hearing therapy. The current study suggests that there is a patient population for whom there is a lack of 273 treatment options and for whom direct stimulation of the cochlea via the implantation of an 274 auditory prosthesis is considered an appropriate intervention. There appears to be strong 275 support amongst the clinical professionals who manage the care of these patients to conduct a 276 clinical trial to evaluate the effectiveness of this novel intervention. A feasibility study is now 277 necessary to determine how many patients would be required for that future trial, whether 278 those patients could be recruited within a reasonable timeframe, and whether the proposed 279 trial design would be acceptable to patients. 280 
Outcome domain Most important 2nd most important Total
Quality of life reported by the patient 38% (11) 17% (5) 55% (16) Ability to understand speech in quiet listening conditions 17% (5) 21% (6) 38% (11) Ability to understand speech in noisy listening conditions 17% (5) 14% (4) 31% (9) Level of listening difficulty reported by the patient 14% (4) 17% (5) 31% (9) I don't know 7% (2) 0% (0) 7% (2) Ability to localise sounds (tell where they are coming from) 3% (1) 0% (0) 3% (1)
Level of effort required to listen reported by the patient 3% (1) 10% (3) 14% (4) Sensitivity to sound (e.g. pure-tone/soundfield audiometry) 0% (0) 7% (2) 7% (2) Other 0% (0) 0% (0) 0% (0) I would always recommend a hearing aid trial to patients with advanced otosclerosis before stapes surgery, as long as the patient is willing.
93% 95%
For otosclerosis patients with BC thresholds worse than 55 dB but who are also outside of CI criteria, either a hearing aid alone or in combination with stapes surgery is the best treatment that is currently available.
I would not recommend stapes surgery for cases of advanced otosclerosis with sloping high-frequency loss because the risks would outweigh the potential benefits to speech perception.
36% 16%
I would not recommend stapes surgery to patients with advanced otosclerosis if their speech discrimination is worse than 30% correct.
57% 37%
There is currently a lack of treatment options for otosclerosis patients with BC thresholds worse than 55 dB, who are outside of CI criteria, and who still struggle with HAs after receiving stapes surgery or if surgery is not recommended.
79% 89%
For patients whose BC thresholds are worse than 55 dB and who are not close to CI criteria, I would not recommend stapes surgery if their airbone gap is less than 20 dB.
64% 63%
I would consider a bone-anchored hearing device for a patient with otosclerosis if their BC thresholds are better than 55 dB.
71% 74%
Patients with otosclerosis whose BC thresholds are 50 dB are approaching the limits of what a bone-anchored hearing device can aid.
86% 89%
I would always recommend a headband trial before surgery to provide a bone-anchored hearing device.
93% 89%
The acoustic gain of a bone-anchored hearing device is insufficient for otosclerosis patients with BC thresholds worse than 55 dB.
86% 89%
I would always recommend stapes surgery to patients with advanced otosclerosis before referring them for a new implantable intervention.
64% 68%
I would not refer otosclerosis patients whose needs are currently unmet by currently-available treatments for a new implantable intervention if their speech discrimination is better than 50% correct.
57% 26%
I would refer otosclerosis patients whose needs are currently unmet by currently-available treatments for a new implantable intervention, as long as there is at least an 80% chance of the patient receiving additional benefit.
71% 89%
I would refer otosclerosis patients whose needs are currently unmet by currently-available treatments for a new implantable intervention even if a conductive component remained, as long as I am sure that their previous stapes surgery was done competently.
64% 68%
Clinical trials are needed to evaluate new treatments for otosclerosis patients whose needs are currently unmet by currently-available treatments.
100% 100%
I would support clinical trials to evaluate treatments for otosclerosis patients whose needs are currently unmet by currently-available treatments. Completed a hearing aid trial
Exclusion criteria
Reports receiving sufficient benefit from acoustic hearing aids
Simultaneously satisfies both of the following criteria: 
